Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2009

01-05-2009 | Original Article

Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines

Authors: Eleonore Fröhlich, Peter Brossart, Richard Wahl

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2009

Login to get access

Abstract

Purpose

Retinoic acid presently is the most advanced agent able to improve the efficacy of radioiodine therapy in differentiated thyroid carcinoma. In order to identify compounds with higher efficacy a panel of pharmacologically well-characterized compounds with antitumour action in solid cancer cell lines was screened.

Methods

The effects of the compounds on iodide uptake, cell number, proliferation and apoptosis were evaluated.

Results

In general, compounds were more effective in cell lines derived from more aggressive tumours. The effectiveness in terms of number of responsive cell lines and maximal increase in iodide uptake achieved decreased in the order: APHA > valproic acid ≈ sirolimus ≈ arsenic trioxide > retinoic acid ≈ lovastatin > apicidine ≈ azacytidine ≈ retinol ≈ rosiglitazone ≈ bortezomib.

Conclusion

We hypothesize that testing of cells from primary tumours or metastases in patients may be a way to identify compounds with optimum therapeutic efficacy for individualized treatment.
Literature
1.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295:2164–7.PubMedCrossRef
2.
Lubina A, Cohen O, Barchana M, Liphshiz I, Vered I, Sadetzki S, Karasik A. Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase. Thyroid 2006;16:1033–40.PubMedCrossRef
3.
Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH, et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006;140:960–6.PubMedCrossRef
4.
Liu YY, Stokkel MP, Pereira AM, Corssmit EP, Morreau HA, Romijn JA, et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol. 2006;154:525–31.PubMedCrossRef
5.
Zhang Y, Jia S, Liu Y, Li B, Wang Z, Lu H, et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun. 2007;28:251–5.PubMedCrossRef
6.
Tepmongkol S, Keelawat S, Honsawek S, Ruangvejvorachai P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008;18:697–704.PubMedCrossRef
7.
Catalano M, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2005;90:1383–9.PubMedCrossRef
8.
Fortunati N, Catalano M, Arena K, Brignardello E, Piovesan A, Boccuzzi G. Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2004;89:1006–9.PubMedCrossRef
9.
Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004;145:2865–75.PubMedCrossRef
10.
Aparicio A, Weber J. Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr Opin Investig Drugs. 2002;3:627–3.PubMed
11.
Provenzano MJ, Fitzgerald MP, Krager K, Domann FE. Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol Head Neck Surg. 2007;137:722–8.PubMedCrossRef
12.
Park EY, Wilder ET, Lane MA. Retinol inhibits the invasion of retinoic acid-resistant colon cancer cells in vitro and decreases matrix metalloproteinase mRNA, protein, and activity levels. Nutr Cancer. 2007;57:66–77.PubMed
13.
Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, et al. A phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer. 2005;41:523–30.PubMedCrossRef
14.
Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab. 2006;91:4013–21.PubMedCrossRef
15.
Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13:758s–63s.PubMedCrossRef
16.
Ai Z, Lu W, Ton S, Liu H, Sou T, Shen Z, et al. Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of cyclin D1 transcription mediated by Sp1 transcription factor. Biochem Biophys Res Commun. 2007;360:684–9.PubMedCrossRef
17.
Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, et al. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat. 2002;3:61–73.CrossRef
18.
Fröhlich E, Czarnocka B, Brossart P, Wahl R. Antitumor effects of arsenic trioxide in transformed human thyroid cells. Thyroid 2008;18:1183–93.PubMedCrossRef
19.
Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6:292–306.PubMedCrossRef
20.
Salvatore G, Carlomagno F, Santoro M. Pros and cons of cellular studies in developing new drugs for thyroid cancers. Thyroid 2008;18:819–22.PubMedCrossRef
21.
Herrera MF, Hay ID, Wu PS, Goellner JR, Ryan JJ, Ebersold JR, et al. Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg. 1992;16:669–74.PubMedCrossRef
22.
23.
Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483–91.PubMed
24.
25.
Coelho S, Vaisman M, Carvalho D. Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des. 2005;11:2525–31.PubMedCrossRef
26.
Coelho S, Corbo R, Buescu A, Carvalho D, Vaisman M. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest. 2004;27:334–9.PubMed
27.
Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29:775–82.PubMedCrossRef
28.
Kitazono M, Robey R, Zhan Z, Sarlis N, Skarulis M, Aikou T, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(−) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab. 2001;86:3430–35.PubMedCrossRef
29.
Ohta K, Endo T, Haraguchi K, Hershman J, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2001;86:2170–7.PubMedCrossRef
30.
van Herle AJ, Agatep ML, Padua DN III, Totanes TL, Canlapan DV, van Herle HML, et al. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro. J Clin Endocrinol Metab. 1990;71:755–63.PubMedCrossRef
31.
van Staveren WC, Solis DW, Delys L, Duprez L, Andry G, Franc B, et al. Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res. 2007;67:8113–20.PubMedCrossRef
32.
Xu J, Moatamed F, Caldwell JS, Walker JR, Kraiem Z, Taki K, et al. Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2003;88:4990–6.PubMedCrossRef
33.
von Wangenheim KH, Peterson HP. Control of cell proliferation by progress in differentiation: clues to mechanisms of aging, cancer causation and therapy. J Theor Biol. 1998;193:663–78.CrossRef
34.
Bruserud O, Gjertsen BT, Huang T. Induction of differentiation and apoptosis – a possible strategy in the treatment of adult acute myelogenous leukemia. Oncologist 2000;5:454–62.PubMedCrossRef
35.
Frohlich E, Macchicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer. 2005;12:1–13.CrossRef
36.
Schmutzler C. Regulation of the sodium/iodide symporter by retinoids – a review. Exp Clin Endocrinol Diabetes. 2001;109:41–4.PubMedCrossRef
37.
Gillam MP, Sidhaye AR, Lee EJ, Rutishauser J, Stephan CW, Kopp P. Functional characterization of pendrin in a polarized cell system. Evidence for pendrin-mediated apical iodide efflux. J Biol Chem. 2004;279:13004–10.PubMedCrossRef
38.
Rillema JA, Hill MA. Pendrin transporter carries out iodide uptake into MCF-7 human mammary cancer cells. Exp Biol Med. (Maywood) 2003;228:1078–82.
39.
Rousset B. How iodide reaches its site of utilisation in the thyroid gland – involvement of solute carrier 26A4 (pendrin) and solute carrier 5A8 (apical iodide transporter). In: Hughes T, Dunn C, McCulloch A, editors. European Endocrine Disease 2007. London: Touch Briefings; 2007. p. 81–3.
40.
Brabant G, Maenhaut C, Kohrle J, Scheumann G, Dralle H, Hoang-Vu C, et al. Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol. 1991;82:R7–12.PubMedCrossRef
41.
Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006;13:797–826.PubMedCrossRef
42.
Hoelting T, Tezelman S, Siperstein AE, Duh QY, Clark OH. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro. Thyroid 1995;5:35–40.PubMedCrossRef
43.
Zielke A, Hoffmann S, Plaul U, Duh QY, Clark OH, Rothmund M. Pleiotropic effects of thyroid stimulating hormone in a differentiated thyroid cancer cell line. Studies on proliferation, thyroglobulin secretion, adhesion, migration and invasion. Exp Clin Endocrinol Diabetes. 1999;107:361–9.PubMed
44.
Demeure MJ, Doffek KM, Wilson SD. Defective thyrotropin receptor G-protein cyclic adenosine monophosphate signaling mechanism in the FTC human follicular thyroid cancer cell line. Surgery 1997;122:1195–201.PubMedCrossRef
45.
Kimura H, Yamashita S, Namba H, Usa T, Fujiyama K, Tsuruta M, et al. Impairment of the TSH signal transduction system in human thyroid carcinoma cells. Exp Cell Res. 1992;203:402–6.PubMedCrossRef
46.
Kebebew E, Wong MG, Siperstein AE, Duh QY, Clark OH. Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function. J Clin Endocrinol Metab. 1999;84:2840–7.PubMedCrossRef
47.
Meireles AM, Preto A, Rocha AS, Rebocho AP, Maximo V, Pereira-Castro I, et al. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 2007;17:707–15.PubMedCrossRef
48.
Schmutzler C, Hoang-Vu C, Ruger B, Kohrle J. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur J Endocrinol. 2004;150:547–56.PubMedCrossRef
49.
Clinckspoor I, Verlinden L, Verstuyf M, Bouillon R, Decallonne B. Effects of 1,25(OH)2D3 and analog WY1112 on proliferation and differentiation of FRO cells. Horm Res. 2007;68(Suppl 3):32.
50.
Spitzweg C, Heufelder AE. The sodium iodide symporter: its emerging relevance to clinical thyroidology. Eur J Endocrinol. 1998;138:374–5.PubMedCrossRef
51.
Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2008; Oct.14 [Epub ahead of print].
52.
53.
Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007;25:4603–9.PubMedCrossRef
54.
55.
Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children’s Oncology Group study. Clin Cancer Res. 2007;13:1516–22.PubMedCrossRef
56.
Tedesco Silva H Jr, Felipe CR, Machado PG, Garcia R, Motegi S, Hosaka BH, et al. Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. Transplant Proc. 2003;35:177S–80S.PubMedCrossRef
57.
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354–60.PubMed
Metadata
Title
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines
Authors
Eleonore Fröhlich
Peter Brossart
Richard Wahl
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-1024-6

Other articles of this Issue 5/2009

European Journal of Nuclear Medicine and Molecular Imaging 5/2009 Go to the issue

Image of the Month

Disseminated tuberculosis infection: a ‘super’ 18F-FDG PET/CT appearance

Letter to the Editor

Ventilation/perfusion SPECT — an essential but underrated method for diagnosis of pulmonary embolism and other diseases

Original article

Molecular imaging of α7 nicotinic acetylcholine receptors: design and evaluation of the potent radioligand [18F]NS10743

Focus on

Nanoparticles for concurrent multimodality imaging and therapy: The dawn of new theragnostic synergies

Original Article

[18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1

Original Article

Diagnostics of “non-acute” vascular prosthesis infection using 18F-FDG PET/CT: our experience with 96 prostheses